Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
182 participants
INTERVENTIONAL
2020-10-01
2021-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic Value of New COVID-19 Antibodies Testing Among Laboratory Healthcare Workers
NCT04445415
Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients
NCT04483622
Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers
NCT04525417
Evaluation of Humoral Immunity Following COVID-19 in Pregnancy
NCT04568044
Mucosal Immunity in Terms of SARS-CoV-2 Antibodies in Saliva After COVID-19 Infection and Vaccination
NCT04842305
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SARS Cov_2 Incidence of Healthy Health Workers
Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hikmet Eda Aliskan
UNKNOWN
Hatice Hale Gumus
UNKNOWN
Ilker Odemis
UNKNOWN
Zuhal Ekici Unsal
UNKNOWN
Baskent University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hasan Yesilagac
Specialist Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Adana Dr. Turgut Noyan Application and Research Center
Adana, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J, Yan F. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-393. doi: 10.1016/j.jinf.2020.02.016. Epub 2020 Feb 26.
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KA20/449
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.